Ber h2

Manufactured by Agilent Technologies

Sourced in Denmark, United States, Germany

The Ber-H2 is a versatile lab equipment product offered by Agilent Technologies. It is designed to perform precise and reliable hydrogen analysis. The core function of the Ber-H2 is to accurately measure the hydrogen content in a variety of sample types.

Automatically generated - may contain errors

Lab products found in correlation

Endogenous peroxidase blocking, by Agilent Technologies (2 mentions) Il 2r 1, by Thermo Fisher Scientific (2 mentions) Oti1d10, by Thermo Fisher Scientific (2 mentions) Mib 1, by Agilent Technologies (2 mentions) Mum1p, by Agilent Technologies (2 mentions) Aria 2, by BD (1 mentions) Alexa fluor 568, by Thermo Fisher Scientific (1 mentions) Alexa fluor 488, by Thermo Fisher Scientific (1 mentions) Bond 3 stainer, by Leica (1 mentions) Carb 3, by Agilent Technologies (1 mentions) Jcb117, by Agilent Technologies (1 mentions) Bcl 2 oncoprotein, by Agilent Technologies (1 mentions) C myc, by Abcam (1 mentions) Palm robot microbeam, by Zeiss (1 mentions) Ish iview blue detection kit, by Roche (1 mentions) Tma master 01, by 3DHISTECH (1 mentions) Bright vision polymer detection system, by Medac (1 mentions) Autostainer 480 s, by Medac (1 mentions) Dab 415192f, by Medac (1 mentions) Envision system, by Agilent Technologies (1 mentions)

Close spelling variants of this product

Clone Ber-H2 CD30 (Ber-H2;

11 protocols using ber h2

Immunohistochemical Staining of Lymphocyte Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols

A pre-treatment consisting of hydrated heating at 96 °C in 10% citrate buffer for 20 min preceded the endogenous peroxidase blocking (DAKO, Glostrup, Denmark) for 5 min and incubation with different primary monoclonal antibodies: IL-2R.1 (1:1.000, overnight 4 °C; ThermoFisher Scientific, Waltham, MA, USA), OTI1D10 (1:250, overnight 4 °C; ThermoFisher Scientific, Waltham, MA, USA), or Ber-H2 (ready to use, 30 min RT; DAKO, Glostrup, Denmark) were used.

Guijarro I.M., Garcés M., Marín B., Otero A., Barrio T., Badiola J.J, & Monzón M. (2020). Neuroimmune Response in Natural Preclinical Scrapie after Dexamethasone Treatment. International Journal of Molecular Sciences, 21(16), 5779.

+ Open protocol

+ Expand

Multiparameter Flow Cytometric Profiling of Hodgkin Lymphoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

For FACS analysis, a standard staining procedure was applied. Each classical Hodgkin lymphoma cell line was harvested, washed, and resuspended in FACS buffer (PBS, 10% FBS, 0.1% NaN₃) to a concentration of 5 × 10⁶ cells/mL. Cells The cells were incubated with primary antibodies against mGluR5 (1:250, Cat# ab27190, Abcam, Cambridge, UK) and CD30 (1:80, Ber-H2, Cat# M0751, Dako, Jena, Germany) for 2 h on ice. The cells were washed thrice with 1× PBS. The secondary antibodies (anti-rabbit-IgG antibody, Alexa Fluor 488, 1:1000, Cat# A-11008, Invitrogen, Waltham, MA, USA and anti-mouse antibody, Alexa Fluor 568, 1:250, Cat# A-11004, Invitrogen) were added and incubated for 2 h on ice. The labeled cells were washed thrice with 1× PBS, centrifuged each time at 500× g for 5 min at 4 °C, and resuspended in 500 μL of ice-cold FACS buffer for flow cytometry. The cells were double-labeled for Hodgkin lymphoma tumor marker CD30 and for cell surface receptor mGluR5. The gating strategy comprised the exclusion of dead cells and debris (forward and side scatter) as well as doublets (plotting height and width against area), and aimed for the double-positive (mGluR5⁺|CD30⁺) cells, using a fluorescence activated cell sorter (FACS) Aria II (Beckton Dickinson, Heidelberg, Germany).

Schnell S., Knierim E., Bittigau P., Kreye J., Hauptmann K., Hundsdoerfer P., Morales-Gonzalez S., Schuelke M, & Nikolaus M. (2023). Hodgkin Lymphoma Cell Lines and Tissues Express mGluR5: A Potential Link to Ophelia Syndrome and Paraneoplastic Neurological Disease. Cells, 12(4), 606.

+ Open protocol

+ Expand

Immunohistochemical Analysis of Tissue Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

Tissue specimens were fixed in 10% formaldehyde, embedded in paraffin, and cut into 3‐μm thick sections. Each section was further stained with hematoxylin and eosin. Immunohistochemical staining was performed on paraffin sections using antibodies against CD3 (1:200, LN10; Novocastra), CD5 (1:100, 4C7; Novocastra), CD10 (1:100, 56C6; Novocastra), CD15 (1:50, Carb‐3; DAKO), CD20 (1:100, L26; DAKO), CD30 (1:40, Ber‐H2; DAKO), CD79a (1:100, JCB117; DAKO), Ki‐67 (1:2500, MIB‐1; DAKO), and PD‐L1 (1:400, E1LN3; Cell Signaling Technology) and samples were analyzed using a Bond III Stainer (Leica Biosystems).

Gion Y., Doi M., Nishimura Y., Ikeda T., Filiz Nishimura M., Sakamoto M., Egusa Y., Nishikori A., Fujita A., Iwaki N., Nakamura N., Yoshino T, & Sato Y. (2021). PD‐L1 expression is associated with the spontaneous regression of patients with methotrexate‐associated lymphoproliferative disorders. Cancer Medicine, 11(2), 417-432.

+ Open protocol

+ Expand

Immunohistochemical Analysis of Lymphoid Neoplasms

Check if the same lab product or an alternative is used in the 5 most similar protocols

Excised tissue specimens were fixed in 10% formalin and embedded in paraffin wax. Serial sections from the paraffin blocks were stained with hematoxylin and eosin. Immunohistochemical analysis was performed according to standard procedures. The antibodies used are as follows: CD3 (1:50, PS1; Leica Biosystems, Newcastle upon Tyne, UK), CD5 (1:50, 4C7; Leica Biosystems), CD10 (1:50, 56C6; Leica Biosystems), CD20 (1:100, L26; Leica Biosystems), CD30 (1:30, Ber-H2; Dako, Glostrup, Denmark), BCL2 oncoprotein (1:50, 124; Dako), BCL6 oncoprotein (1:100, LN22, Leica Biosystems), multiple myeloma oncogene 1 (MUM1; 1:50, MUM1p; Dako), cyclin D1 (1:100, DCS-6; Nichirei Biosciences Inc., Tokyo, Japan), Ki-67 (1:100, MIB-1; Dako), and c-MYC (1:200, Y69; Abcam plc., Cambridge, UK). Positivity was evaluated using cut-off values of 40% for MYC and 20% for others.

Kabasawa N., Shiozawa E., Murai S., Homma M., Uesugi Y., Matsui T., Nakata A., Shimada S., Sasaki Y., Baba Y., Watanuki M., Arai N., Fujiwara S., Kawaguchi Y., Tsukamoto H., Uto Y., Yanagisawa K., Hattori N., Sakai H., Harada H., Nakamaki T., Takimoto M, & Yamochi-Onizuka T. (2021). Increased MYC expression without MYC gene translocation in patients with the diffuse large B-cell-lymphoma subtype of iatrogenic immunodeficiency-associated lymphoproliferative disorders. Journal of Clinical and Experimental Hematopathology : JCEH, 61(3), 120-125.

+ Open protocol

+ Expand

Laser-Microdissection of CD30+ B Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Frozen lymph node sections positioned on membrane-covered microdissection slides were immunostained for CD30 with the anti-CD30 antibody BerH2 (Dako). Single CD30⁺ B cells were microdissected into 20 µl of 1 x PCR buffer using the PALM Robot MicroBeam laser microdissection system (Zeiss, Oberkochen, Germany) as previously described (11 (link)). Microdissected pieces of membrane not covered by tissue and tubes only carrying PCR buffer served as negative controls.

Küppers R., Budeus B., Hartmann S, & Hansmann M.L. (2023). Clonal composition and differentiation stage of human CD30+ B cells in reactive lymph nodes. Frontiers in Immunology, 14, 1208610.

+ Open protocol

+ Expand

Immunohistochemical Profiling of PTLD Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

Primary diagnostic formalin fixed paraffin-embedded tissue samples containing representative PTLD were available from 52 patients; samples of these were included in a tissue microarray (TMA). Briefly, three 1-mm diameter tissue cores were identified in tumor areas, punched out and re-embedded in recipient blocks using a TMA master-01 (3DHISTECH Ltd., Budapest, Hungary).
Immunohistochemical stains were performed on 4 μm formalin fixed paraffin-embedded tissue sections according to standard antibody-specific protocols, optimized in house for use with the Ventana Benchmark automated staining system (Ventana Medical Systems, Tucson, AZ). For review of the classification of the tumors according to WHO 2008 criteria, a panel of markers was applied consisting of CD3 (polyclonal, Dako, Glostrup, Denmark), CD5 (SP19, Ventana Medical Systems), CD4 (SP35, Ventana), CD8 (SP57, Ventana), CD10 (SP67, Ventana), CD20 (L26, Ventana), CD79a (MRQ-48, Ventana), CD30 (Ber-H2, Dako) and MUM1 (MUM1P, Dako). The EBV antigens were visualized using antibodies to LMP (LMP clones CS.1-4, Dako) and EBNA2 (PE2; Abcam, Cambridge, UK). EBV-RNA (EBER) expression was identified by in-situ hybridization (ISH iView Blue Detection kit; Ventana). In each case, EBV status in the PTLD cell population was evaluated by the authors (S.H.D. and M.V.) and recorded as either positive or negative.

Vase M.Ø., Maksten E.F., Strandhave C., Søndergaard E., Bendix K., Hamilton-Dutoit S., Andersen C., Møller M.B., Sørensen S.S., Kampmann J., Eiskjær H., Iversen M., Weinreich I.D., Møller B., Jespersen B, & d'Amore F. (2015). HLA Associations and Risk of Posttransplant Lymphoproliferative Disorder in a Danish Population-Based Cohort. Transplantation Direct, 1(7), e25.

+ Open protocol

+ Expand

Immunohistochemical Analysis of CD30 Expression

Check if the same lab product or an alternative is used in the 5 most similar protocols

A total of 4 × 10⁴ tumour cells in PBS/1.5% BSA were cytospun at 12000 g for 5′ onto glass slides and air‐dried for 15′. Signal detection was performed semiautomatically in the Autostainer 480 S (Medac, Wedel, Germany) using the Bright Vision+ polymer detection system (Medac) and the following settings: anti‐CD30 primary antibody (BER‐H2, dilution 1:200, Dako, Eching, Germany) for 20′, enhancer for 10′, polymer (Poly‐HRP‐Goat anti‐mouse/‐rabbit‐IgG) for 20′, 3,3′‐diaminobenzidine (DAB) (415192F, Medac) for 8′. Nuclei were stained by haematoxylin for 3′.

Schönberger S., van Beekum C., Götz B., Nettersheim D., Schorle H., Schneider D.T., Casati A., Craveiro R.B., Calaminus G, & Dilloo D. (2017). Brentuximab vedotin exerts profound antiproliferative and pro‐apoptotic efficacy in CD30‐positive as well as cocultured CD30‐negative germ cell tumour cell lines. Journal of Cellular and Molecular Medicine, 22(1), 568-575.

+ Open protocol

+ Expand

CD30 Immunohistochemistry for Tumor Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry was performed on a representative whole tissue section for each case. Heat-induced epitope retrieval was performed using Target Retrieval Solution, High pH (Dako, Glostrup, Denmark) in a water bath (98°C). The slides were incubated with the anti-CD30 monoclonal antibody (Ber-H2, dilution 1:100; Dako) for 1 h and subsequently labeled using the EnVision system (Dako). CD30 positivity was defined as membranous/cytoplasmic staining in at least 5% of tumor cells. CD30 expression in intratumoral activated lymphocytes, when present, was excluded from evaluation. Staining intensity was semi-quantitatively graded as weak, moderate, or strong. The extent of staining was classified as negative (0 to <5%), 5–25%, 26–50%, 51–75%, and 76–100%. According to NordiQC recommendation ³⁷, a tonsillar tissue was used as a control, in which scattered activated lymphocytes were stained positively. Immunohistochemical results for PanTRK, CD34, and S100 protein were also recorded if they had been performed during the original diagnosis or in previous research.

Kojima N., Mori T., Motoi T., Kobayashi E., Yoshida M., Yatabe Y., Ichikawa H., Kawai A., Yonemori K., Antonescu C.R, & Yoshida A. (2023). Frequent CD30 expression in an emerging group of mesenchymal tumors with NTRK, BRAF, RAF1, or RET fusions. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 36(4), 100083.

+ Open protocol

+ Expand

Immunohistochemical Staining Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

A pre-treatment consisting of hydrated heating at 96 °C in citrate buffer 10% for 20 min preceded the endogenous peroxidase blocking (DAKO, Glostrup, Denmark) for 5 min and incubation with different primary monoclonal antibodies: IL-2R.1 (1:1000, overnight 4 °C; ThermoFisher Scientific, Waltham, MA, USA), OTI1D10 (1:250, overnight 4 °C; ThermoFisher Scientific, Waltham, MA, USA) or Ber-H2 (ready to use, 30 min RT; DAKO, Glostrup, Denmark).

Guijarro I.M., Garcés M., Andrés-Benito P., Marín B., Otero A., Barrio T., Carmona M., Ferrer I., Badiola J.J, & Monzón M. (2021). Neuroimmune Response Mediated by Cytokines in Natural Scrapie after Chronic Dexamethasone Treatment. Biomolecules, 11(2), 204.

+ Open protocol

+ Expand

Immunohistochemical Analysis of CD30+ Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Formalin-fixed and paraffin-embedded (FFPE) biopsies of reactive lymph nodes for which parts were also available as frozen tissue were stained for CD30 with the anti-CD30 monoclonal antibody BerH2 (Dako, Hamburg, Germany) to identify lymph nodes with a substantial number of CD30⁺ cells. Five of the eight cases included in the IGHV gene analysis were further characterized by double stainings for CD30 (clone EP154, Diagnostic Biosystems, Pleasanton, CA, USA, at dilution 1:100) combined with staining for PAX5 (clone DAK-PAX5, Dako, at dilution 1:100), CD138 (clone MI15, Dako, at dilution 1:100), or MUM1/IRF4 (clone MUM1P, Dako, at dilution 1:100). The double stainings were performed using the Vecta Fluor Duet Double Labeling Kit DK-8828, Vector Laboratories, Newark, CA, USA.

Küppers R., Budeus B., Hartmann S, & Hansmann M.L. (2023). Clonal composition and differentiation stage of human CD30+ B cells in reactive lymph nodes. Frontiers in Immunology, 14, 1208610.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!